首页> 外文期刊>International journal of sports medicine >Analgesic efficacy and safety of the diclofenac epolamine topical patch 1.3% (DETP) in minor soft tissue injury.
【24h】

Analgesic efficacy and safety of the diclofenac epolamine topical patch 1.3% (DETP) in minor soft tissue injury.

机译:双氯芬酸依波明局部贴剂1.3%(DETP)在轻度软组织损伤中的镇痛效果和安全性。

获取原文
获取原文并翻译 | 示例
           

摘要

The diclofenac epolamine topical patch 1.3% was designed to deliver analgesic concentrations of diclofenac to an underlying soft tissue injury site, while limiting systemic exposure to diclofenac. This randomized, double-blind, placebo-controlled study evaluated the safety and efficacy of the diclofenac epolamine topical patch for the treatment of acute pain due to minor soft tissue injury. Patients (18-65 years, inclusive) with clinically significant minor soft tissue injuries (mild or moderate sprain, strain, or contusion) incurred within 7 days of study entry and having pain scores >/= 5 on a Visual Analog Scale of 0-10 were enrolled. Patients were randomized to receive the diclofenac epolamine topical patch (n=207) or placebo patch (n=211) application twice daily for 14 days or until pain resolution. Patients recorded pain scores every 12 h at the time of patch removal using the Visual Analog Scale. Investigator-assessed global response to therapy was also evaluated. Safety data were collected throughout the study. Twice-daily treatment with diclofenac epolamine topical patch produced a statistically significant reduction in mean pain score relative to baseline by an additional 18.2% in the diclofenac epolamine topical patch group (0.435 +/- 0.268) compared with the placebo group (0.532 +/- 0.293) (p=0.002; overall) beginning after application of the second patch. Consistent with this treatment effect, median time to pain resolution was shortened by 2 days in the diclofenac epolamine topical patch group relative to the placebo group (p=0.007). These results were reinforced independently by investigators who reported treatment as good or excellent for 58% of diclofenac epolamine topical patch-treated patients compared with 49% in the placebo patch group (p=0.008). The most common adverse events were treatment site related (n=16, 7.9% diclofenac epolamine topical patch; n=12, 5.8% placebo patch). Most (80%) patients reported tolerability as excellent or good. In conclusion, the diclofenac epolamine topical patch provides effective, rapid pain relief for the treatment of acute pain from minor soft tissue injury and appears generally safe and well tolerated.
机译:双氯芬酸依泊拉明局部贴剂1.3%用于将镇痛药浓度的双氯芬酸递送至潜在的软组织损伤部位,同时限制全身暴露于双氯芬酸。这项随机,双盲,安慰剂对照的研究评估了双氯芬酸依泊明局部贴剂治疗因轻度软组织损伤而引起的急性疼痛的安全性和有效性。在研究进入7天内发生临床上严重的轻度软组织损伤(轻度或中度扭伤,拉伤或挫伤)的患者(包括18-65岁),其视觉模拟评分为0-,疼痛评分> / = 5招募了10名。患者随机接受双氯芬酸依泊明局部贴剂(n = 207)或安慰剂贴剂(n = 211)的应用,每天两次,持续14天或直到疼痛缓解。使用Visual Analog Scale,患者在去除贴剂时每12小时记录一次疼痛评分。还评估了研究者评估的对治疗的总体反应。在整个研究中收集安全性数据。与安慰剂组(0.532 +/-)相比,双氯芬酸依泊明局部贴剂组(0.435 +/- 0.268)每天两次进行双氯芬酸依泊敏局部贴剂的治疗,相对于基线,平均疼痛评分在统计学上显着降低18.2% 0.293)(p = 0.002;总体)在应用第二个补丁后开始。与这种治疗效果一致,双氯芬酸依波明局部贴剂组的疼痛缓解时间中位数相对于安慰剂组缩短了2天(p = 0.007)。研究人员独立地加强了这些结果,他们报告称58%的双氯芬酸依波明局部贴剂治疗的患者为好或优,而安慰剂贴剂组为49%(p = 0.008)。最常见的不良事件与治疗部位有关(n = 16,7.9%双氯芬酸依泊明局部贴剂; n = 12,5.8%安慰剂贴剂)。大多数(80%)患者报告的耐受性为优秀或良好。总之,双氯芬酸依泊明局部贴剂可有效,快速地缓解疼痛,以治疗轻度软组织损伤引起的急性疼痛,并且通常看起来安全且耐受良好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号